Bicara Therapeutics (NASDAQ:BCAX) Issues Earnings Results

Bicara Therapeutics (NASDAQ:BCAX) issued its earnings results on Monday. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.22), FiscalAI reports.

Here are the key takeaways from Bicara Therapeutics’ conference call:

• Bicara said its pivotal FORTIFI-HN01 trial has reached substantial enrollment and still expects a top-line interim analysis in mid-2027. The company now plans to include an interim overall-survival analysis, but has not specified its timing or scope.
• Bicara highlighted phase I-B results for FICERA plus pembrolizumab in HPV-negative head and neck cancer: a 54% confirmed response rate, 25% complete response rate, median duration of response of nearly 22 months, and median overall survival just over 21 months. These are early-stage results; the pivotal trial remains blinded and will test whether the findings are confirmed.
• Recent results from a competitor have increased focus on the evolving treatment landscape and potential competition. Bicara argues that FICERA’s HPV-negative-only strategy and response depth could differentiate it, while acknowledging that survival maturity, subgroup outcomes, and regulatory paths remain uncertain.
• Bicara ended the quarter with about $442 million in cash, equivalents, and marketable securities, which it expects to fund operations into the first half of 2029, including the pivotal trial through final overall-survival analysis and launch preparations. Operating expenses rose year over year as the company advanced trials and expanded its organization.

Bicara Therapeutics Stock Up 15.4%

Shares of NASDAQ BCAX opened at $9.98 on Tuesday. The company has a market cap of $660.38 million, a P/E ratio of -3.22 and a beta of -0.33. Bicara Therapeutics has a 52 week low of $7.87 and a 52 week high of $30.99. The business has a 50-day simple moving average of $17.89 and a two-hundred day simple moving average of $20.91.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on BCAX. Wall Street Zen lowered shares of Bicara Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 31st. BMO Capital Markets began coverage on shares of Bicara Therapeutics in a report on Tuesday, August 18th. They issued an “outperform” rating and a $35.00 price objective for the company. HSBC downgraded shares of Bicara Therapeutics to an “equal weight” rating in a report on Tuesday, September 22nd. Benchmark reiterated a “buy” rating on shares of Bicara Therapeutics in a research note on Thursday, October 29th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Friday, October 2nd. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $30.73.

Insider Buying and Selling at Bicara Therapeutics

In other news, CEO Ryan Cohlhepp sold 17,500 shares of the company’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $22.90, for a total transaction of $400,750.00. Following the sale, the chief executive officer directly owned 181,641 shares in the company, valued at $4,159,578.90. This represents a 8.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.80% of the stock is currently owned by corporate insiders.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its research focuses on therapies designed to target cancer cells while also addressing features of the tumor environment that can suppress immune responses.

The company’s lead investigational program, ficerafusp alfa (BCA101), is a bifunctional antibody designed to bind EGFR, a protein found on some tumor cells, and block TGF-beta, a signaling protein that can contribute to tumor growth and immune suppression.